News
GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback